Acute coronary syndrome management

Please note OSCEstop content is for educational purposes only and not intended to inform clinical practice. OSCEstop and authors take no responsibility for errors or the use of any information displayed. 

Initial ABCDE approach

Follow usual ABCDE approach if critically ill.

Short-term management of ACS

Initial management – MOAN

• Morphine: 10mg in 10ml slow IV – titrate to pain (+ 10mg metoclopramide IV)
• Oxygen: only if saturations below target range
• Aspirin: 300mg PO loading dose (then 75mg OD)
• Nitrates: sublingual GTN if not hypotensive (then PRN)

Other medications 

• Second antiplatelet and anticoagulant: 
  • P2Y₁₂-receptor inhibitor (prasugrel or ticagrelor or clopidogrel) – cardiologist will start during PCI
  • ACS-dose anticoagulation (fondaparinux or unfractionated heparin)
    • in STEMI patients/patients having immediate PCI, cardiologist will start during PCI
    • in NSTEMI patients not having immediate PCI, start before PCI if low bleeding risk
• Early long term medications to consider:
  • β-blocker 
  • ACE-inhibitor (once haemodynamically stable)
  • Statin

Reperfusion therapy (Percutaneous Coronary Intervention – PCI)

• STEMI → immediate PCI (<2h)
• Non-ST elevation ACS
  • Very high-risk (haemodynamically unstable, acute heart failure, arrhythmias, ongoing/recurrent pain/ischaemic changes, mechanical complications) → immediate PCI (<2h)
  • High-risk (rise and fall in troponin compatible with MI, dynamic ischaemic changes, GRACE score >140) → early PCI (<24h)
  • Intermediate-risk (GRACE score >109, diabetes, renal impairment, left ventricular systolic dysfunction, early post-infarction angina, prior PCI/CABG) → PCI (<72h) 
  • Low-risk (none of above features) → non-invasive testing (e.g. stress echocardiography) or PCI (<72h) may be appropriate

Other points

• All patients should have an echocardiogram to assess LV function
• Check electrolytes regularly and ensure patients are on cardiac monitoring while in hospital
• STEMI patients with complete revascularisation may be discharged after 2-3 days; low-risk NSTEMI patients with complete revascularisation may be discharged within 24 hours

Long-term management of ACS

Antiplatelet therapy 

• Patient without AF: aspirin (lifelong) + ticagrelor/prasugrel/clopidogrel (for 1 year)
• Patient with AF: DOAC (lifelong) + clopidogrel (for 1 year) + aspirin (for 1 week)
• Give with PPI if patient is at risk of GI bleeding

NB: durations depend on bleeding and thrombosis risk, and they may modified on a case-by-case basis. 

Cardiovascular risk reduction

• Statin
• BP control
• Lifestyle modifications/cardiac rehabilitation and smoking cessation 

Other treatments 

• β-blocker (lifelong if LV dysfunction; for at least 1 year and consideration of lifelong use if not)
• ACE inhibitor (lifelong)
• Aldosterone antagonist, e.g. eplerenone (if LV dysfunction) 

References: NICE ‘NG185 Acute coronary syndromes’ 2020; European Society of Cardiology ‘Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation’ 2020; European Society of Cardiology ‘Guidelines on Management of Acute Myocardial Infarction in Patients Presenting with ST-Segment Elevation’ 2017

Want to find out how 99% of people passed their exams?

Test your knowledge

Now for some stations!

1. Acute assessment – chest pain
2. STEMI
3. Chest pain history 1
4. Chest pain history 2
5. More here!